Effectiveness of hemoperfusion (HP) in hemodialysis (HD) patients with Covid-19 infection

INTRODUCTION: The aims of this study are to observe the clinical course of all patients affected by infection with SARS-CoV-2 undergoing HD focusing on the impact of HP. METHODS: Patients were divided into Group A: HD sessions with HP and Group B: patients without HP. We registered all the data regarding patients’ clinical course. RESULTS: 13 patients have been enrolled in group A. 9 patients were discharged from the hospital after 43 days (range: 35–56). 30 days was the mean hospitalization stay for the deceased. We did not observe any side effects with HP cartridges. 9 patients did not receive HP during their hospitalization. For those who represented as symptomatic, 8 out of 9 patients died after 6 days of hospitalization (range: 1–14), 2 of them in ICU. CONCLUSION: HP seems to be a helpful, safe and quite efficient tool in the battle against Covid-19 in HD patients.